About the Cancer Diagnostic Devices Market
An increase in any particular internal and external factor can lead to cancer. Currently, the demand for cancer therapy and research in complex molecular tumor diagnostics is high. Researchers are using automated solutions to isolate genetic materials from small tissue samples. The complex genetic analysis of samples using next-generation sequencing technologies helps researchers analyze the individual and relevant pattern of genetic changes in tumor tissues, helping in determining the most effective treatment options.
The development of sophisticated technologies such as microarray, next-generation sequencing, mass spectrometry, automated DNA sequencing, fluorescence in-situ hybridization, and comparative genomic hybridization has opened new avenues for cancer biomarkers. These technologies are capable of detecting abnormalities in the gene expression and the genetic structure of cancer cells. In addition, these technologies can analyze changes in the DNA, RNA, and chromosomes from tissue samples of a tumor.
Technavio’s analysts forecast the global cancer diagnostics devices market to grow at a CAGR of 18.07% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer diagnostics devices market for 2016-2020 To calculate the market size, we consider revenue generated from the sales of molecular and companion cancer diagnostic devices.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Cancer Diagnostics Devices Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the operating in this market.
Key vendors
• Abbott Diagnostics
• Agilent Technologies
• BD
• bioMérieux
• Qiagen
• Roche Diagnostics
Other prominent vendors
• Affymetrix
• Ambry Genetics
• Annoroad
• Aviva Biosciences
• Biochain
• Bio-Rad
• Cancer Genetics
• Cepheid
• CompanionDx
• DiagnoCure
• Epic Sciences
• Epigenomics
• Genomic Health
• HalioDX
• Hologic
• Illumina
• Myriad Genetics
• Thermo Fisher Scientific
• Ventana Medical Systems
• Vysis
Market driver
• Demand for personalized medicines
• For a full, detailed list, view our report
Market challenge
• High cost of developing companion diagnostics
• For a full, detailed list, view our report
Market trend
• Demand for personalized medicines
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Cancer statistics
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Reimbursement and coverage: An overview
• Current scenario: Validating diagnostic tests
• Reimbursement structure in US
• Reimbursement structure in EU
PART 08: Cancer diagnostic devices: Pricing scenario
PART 09: Market segmentation by product
• Global companion cancer diagnostic devices market
• Global molecular cancer diagnostic devices market
PART 10: Market segmentation by cancer type
• Lung cancer
• Breast cancer
• Colorectal cancer
• Prostate cancer
• Cervical cancer
PART 11: Geographical segmentation
• Cancer diagnostic devices market in Americas
• Cancer diagnostic devices market in EMEA
• Cancer diagnostic devices market in APAC
PART 12: Market drivers
• Prevalence of cancer
• Need for cost-cutting in drug discovery and development
• Demand for personalized medicines
• Advances in technology
• Focus on emerging countries
PART 13: Impact of drivers
PART 14: Market challenges
• Unfavorable reimbursement scenario
• High cost of developing companion diagnostics
• Stringent regulatory framework
• Lack of skilled personnel
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Adoption of various strategies
• Increase in R&D
• Product approvals and launches
PART 17: Vendor landscape
• Competitive scenario
• Keys news
• M&A
PART 18: Key vendors
• Abbott Diagnostics
• Agilent Technologies
• BD
• bioMérieux
• Qiagen
• Roche Diagnostics
• Other prominent vendors
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
Exhibit 01: Product offerings
Exhibit 02: Prevalent cancer types worldwide 2012
Exhibit 03: Top countries with highest cancer rate worldwide 2012
Exhibit 04: Cancer statistics by gender 2012
Exhibit 05: Global cancer diagnostic devices market 2015-2020 ($ billions)
Exhibit 06: Five forces analysis
Exhibit 07: Reimbursement perspectives of healthcare entities
Exhibit 08: Factors influencing cost of cancer diagnostic devices
Exhibit 09: Global cancer diagnostic devices market segmentation by product
Exhibit 10: Global companion cancer diagnostic devices market 2015-2020 ($ millions)
Exhibit 11: Global molecular cancer diagnostic devices market 2015-2020 ($ billions)
Exhibit 12: Global cancer diagnostic devices market segmentation by cancer type 2015
Exhibit 13: Cancer types and associated diagnosis methods
Exhibit 14: Global cancer diagnostic devices market segmentation by geography 2015
Exhibit 15: Global cancer diagnostic devices market segmentation by geography 2020
Exhibit 16: Global cancer diagnostic devices market segmentation by geography 2015-2020 ($ millions)
Exhibit 17: Global cancer diagnostic devices market segmentation by geography 2015-2020
Exhibit 18: Cancer diagnostic devices market in Americas 2015-2020 ($ billions)
Exhibit 19: Cancer diagnostic devices market in EMEA 2015-2020 ($ millions)
Exhibit 20: Cancer diagnostic devices market in APAC 2015-2020 ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Abbott Diagnostics: Product portfolio
Exhibit 24: Abbott Diagnostics: Key takeaways
Exhibit 25: Agilent Technologies: Product portfolio
Exhibit 26: Agilent Technologies: Revenue of diagnostics and genomics segment 2013-2015 ($ millions)
Exhibit 27: Agilent Technologies: Key takeaways
Exhibit 28: BD: Product portfolio
Exhibit 29: BD: Revenue of life sciences segment 2013-2015 ($ billions)
Exhibit 30: BD: Key takeaways
Exhibit 31: bioMérieux: Product portfolio
Exhibit 32: bioMérieux: Key takeaways
Exhibit 33: Qiagen: Product portfolio
Exhibit 34: Qiagen: Revenue of consumable and related products 2013-2015 ($ billions)
Exhibit 35: Qiagen: Key takeaways
Exhibit 36: Roche Diagnostics: Product portfolio
Exhibit 37: Roche Diagnostics: Revenue of molecular diagnostics segment 2013-2015 ($ billions)
Exhibit 38: Roche Diagnostics: Key takeaways
Exhibit 39: Other prominent vendors
